Know Cancer

or
forgot password

A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia


Phase 2
18 Years
N/A
Open (Enrolling)
Both
Leukemia

Thank you

Trial Information

A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia


OBJECTIVES:

- Determine the response rate in adult patients with relapsed or refractory acute myeloid
leukemia or acute lymphoblastic leukemia treated with high-dose cytarabine followed by
clofarabine.

OUTLINE: This is an open-label phase II study. Patients are stratified according to
diagnosis (acute myeloid leukemia vs acute lymphoblastic leukemia Phase II: Patients receive
high-dose cytarabine followed by clofarabine (at the dose determined in phase I) on days
1-3.

After completion of study treatment, patients are followed periodically for up to 5 years.

PROJECTED ACCRUAL: A total of 39 patients were accrued for this study.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Pathologic confirmation of acute myeloid leukemia (AML) or acute lymphoblastic
leukemia (ALL)

- No M3 AML

- Meets 1 of the following criteria:

- In first relapse

- In second relapse after a second complete remission (CR) that lasted ≥ 3 months

- Refractory to initial induction therapy

- No symptomatic CNS involvement

PATIENT CHARACTERISTICS:

- ECOG performance status ≤ 2

- Creatinine < 2 mg/dL

- Bilirubin ≤ 2 mg/dL

- AST and ALT ≤ 4 times upper limit of normal

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for 2 weeks after
completing study treatment

- Ejection fraction ≥ 45% by echocardiogram

- No active, uncontrolled systemic infection considered opportunistic,
life-threatening, or clinically significant

- No psychiatric disorders that would interfere with giving consent, study
participation, or follow-up procedures

- No other severe concurrent disease that would preclude study treatment

PRIOR CONCURRENT THERAPY:

- At least 1 week since prior therapy and recovered

- No other concurrent chemotherapy

- Hydroxyurea to control WBC count before starting study treatment allowed

- No concurrent corticosteroids unless used for diseases other than leukemia

- No concurrent palliative radiotherapy

- No concurrent growth factors (e.g., epoetin alfa, filgrastim [G-CSF], or sargramostim
[GM-CSF]) in patients with AML

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Measure Patient Response to High-dose Cytarabine Followed by Clofarabine in Adult Patients With Relapsed or Refractory AML

Outcome Description:

Response to the therapy is measured by a defined improvement in Neutrophil and platlet counts, along with improved cellularity of bone marrow biopsy (>20% with maturation of all cell lines), <5% blasts, auer rods must not be detectable and extramedullary leukemia or soft tissue involvment must not be present.

Outcome Time Frame:

5 weeks

Safety Issue:

No

Principal Investigator

Bayard L. Powell, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Comprehensive Cancer Center of Wake Forest University

Authority:

United States: Institutional Review Board

Study ID:

21204 Phase 2

NCT ID:

NCT01656031

Start Date:

February 2005

Completion Date:

Related Keywords:

  • Leukemia
  • recurrent adult acute lymphoblastic leukemia
  • recurrent adult acute myeloid leukemia
  • adult acute myeloid leukemia with 11q23 (MLL) abnormalities
  • adult acute myeloid leukemia with inv(16)(p13;q22)
  • adult acute myeloid leukemia with t(16;16)(p13;q22)
  • adult acute myeloid leukemia with t(8;21)(q22;q22)
  • adult acute basophilic leukemia
  • adult acute eosinophilic leukemia
  • adult erythroleukemia (M6a)
  • adult pure erythroid leukemia (M6b)
  • adult acute megakaryoblastic leukemia (M7)
  • adult acute minimally differentiated myeloid leukemia (M0)
  • adult acute monoblastic leukemia (M5a)
  • adult acute monocytic leukemia (M5b)
  • adult acute myeloblastic leukemia with maturation (M2)
  • adult acute myeloblastic leukemia without maturation (M1)
  • adult acute myelomonocytic leukemia (M4)
  • Leukemia
  • Leukemia, Lymphoid
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid

Name

Location
Wake Forest University Comprehensive Cancer Center Winston-Salem, North Carolina  27157-1096